The historical rank and industry rank for Innovent Biologics's Operating Margin % or its related term are showing as below:
HKSE:01801'
s Operating Margin % Range Over the Past 10 Years
Min: -16383.15 Med: -45.42 Max: 16.42
Current: 16.39
HKSE:01801's Operating Margin % is ranked better than 85.73% of 939
companies
in the Biotechnology industry
Industry Median: -86.77
vs HKSE:01801: 16.39
Innovent Biologics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Innovent Biologics Operating Margin % Related Terms
Innovent Biologics Operating Margin % Historical Data
* Premium members only.
The historical data trend for Innovent Biologics's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01801 vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Innovent Biologics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Innovent Biologics's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics (HKSE:01801) has a Operating Margin % of 11.95% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Innovent Biologics and its competitors. According to the industry distribution chart, Innovent Biologics ranks #134 out of 939 companies in the Biotechnology industry, placing it in the top 14.3%.
Is Innovent Biologics' Operating Margin % too high?
Innovent Biologics' current Operating Margin % is 11.95%. Based on the distribution chart, Innovent Biologics ranks #134 out of 939 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Innovent Biologics has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovent Biologics ranks #134 out of 939 companies for Operating Margin %. This places Innovent Biologics in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Innovent Biologics and its competitors. Innovent Biologics's current Operating Margin % is 11.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (HKSE:01801) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$99.69, compared to a current price of HK$87.80 — trading 11.9% below its estimated fair value. The current Operating Margin % is 11.95%. Innovent Biologics' overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Innovent Biologics (HKSE:01801), the current Operating Margin % is 11.95% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (HKSE:01801) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued.
The current stock price of HK$87.80 is trading 11.9% below its estimated GF Value™ of HK$99.69.
GuruFocus considers Innovent Biologics to be Modestly Undervalued.
Key valuation signals for HKSE:01801:
Operating Margin %: 11.95%
GF Value™: HK$99.69 vs. price of HK$87.80 (11.9% below fair value)
No single metric tells the full story. See the HKSE:01801 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
83GF Score
Get the complete analysis for HKSE:01801
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01801 has been successfully added to your 
